GENFIT is a late-stage biopharmaceutical company dedicated to innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs. Its lead candidate, elafibranor, is currently being evaluated in a pivotal Ph 3 clinical trial (“RESOLVE-IT”) as a potential treatment for NASH, with data expected by YE. GENFIT was recently granted orphan drug designation for PBC following positive Ph 2 results reported in December 2018. The Company announced a $228M partnership with Terns Pharmaceutical to develop and commercialize its lead candidate in Greater China. The Company also announced a NASH biomarker diagnostic program and a signed licensing agreement with LabCorp to expand access to innovative NASH diagnostic test for the clinical research market.
Anti-inflammatory, Metabolic Disorders
500MM - 1B
245, First Street, 18th Floor
Cambridge, MA 02142
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by